SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-35.
  • 2
    Howard MA, Duvall D, Terrell DR, Christopher A, Thomas I, Holloway N, Vesely SK, George JN. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the six year experience of the Oklahoma TTP-HUS Study Group. J Clin Apher 2003;18:16-20.
  • 3
    Johnson KK, Duvall D, Gilcher RO, Smith JW, Forsberg JE, Terrell DR, Vesely SK, George JN. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service. J Okla State Med Assoc 2007;100:273-8.
  • 4
    Kitzinger J. Qualitative research: introducing focus groups. BMJ 1995;311:299-302.
  • 5
    Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;101:60-8.
  • 6
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
  • 7
    Bianchi V, Robles R, Alberio L, Furlan M, Von Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-3.
  • 8
    Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100.
  • 9
    Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF72 assay: comparison with other assay methods. J Thromb Haemost 2006;4:1146-8.
  • 10
    Ware JE, Kosinski M. SF-36 physical and mental health summary scales: a manual for users of version 1. Lincoln (RI): QualityMetric Inc.; 2001.
  • 11
    Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? In: GewirtzAM, WinterJN, ZuckermanK, editors. Hematology 2007. Washington, DC: American Society of Hematology; 2007. p. 121-6.
  • 12
    Lewis QF, Scott JG, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, George JN. Neurocognitive impairment following recovery from ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood 2007;110:395a.
  • 13
    Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura. Transfusion 2008;48:382-92.
  • 14
    Patschan D, Witzke O, Duhrsen U. Acute myocardial infarction in thrombotic microangiopathies—clinical characteristics, risk factors, and outcome. Nephrol Dial Transplant 2006;21:1549-54.